Their presentation addressed “Infringement, Knowledge, and Intent—Proving Inducement in the Life Sciences.” Specific topics included:
- What evidence is sufficient to show intent in the ANDA/BLA context versus when a product is on the market?
- What impacts will GSK v. Teva have on the future of skinny-labeling?
- How can the regulatory process affect the chances of proving inducement?
The IP Forum for Life Sciences took place Dec. 4-7 at the Biltmore Hotel Miami in Coral Gables, Fla. The event was presented by Consero.